secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0000950170-23-050440
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista stockholders approve officer exculpation amendment, elect directors
----------------------------------------------------------------------------

- Approved certificate of amendment to limit officer liability under Delaware law (20.2M for, 2.5M against).
- Elected Patrick Treanor and Edward W. Unkart as Class II directors for three-year terms.
- Ratified Deloitte & Touche as independent auditor for FY ending April 30, 2024 (30.8M for, 1.6K against).
- Non-binding advisory vote on named executive officer compensation passed (20.0M for, 2.7M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/kalv-20230926.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-050440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer